Program
MET233
A development code. Also written as “MET233 and MET097”.
Its studies are mostly in Obesity, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 20 open or running | phase 2since Apr 3, 2025 | Apr 3, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2025First study: phase 2 study in ObesityFirst studyNCT06924320 · 201 enrolled · United States
- Jun 6, 2025Phase 1 study in ObesityNCT07022977 · 145 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07022977Obesity · United States | 1 | Completed | May 28, 2026 | 145 |
| NCT06924320Obesity · United States | 2 | Completed | Sep 29, 2026 | 201 |
How it is read
Names in the registry
- “MET233”, 1 entry
- “MET233 and MET097”, 1 entry
Codes read as this program: MET233.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.